The serine protease inhibitor of Kazal-type 9 (SPINK9) is expressed in lichen simplex chronicus, actinic keratosis and squamous cell carcinoma.
The serine protease inhibitor of Kazal-type 9 (SPINK9) is expressed in lichen simplex chronicus, actinic keratosis and squamous cell carcinoma.
复制标题
Kazal 9 型丝氨酸蛋白酶抑制剂 (SPINK9) 在慢性单纯性地衣、光化性角化病和鳞状细胞癌中表达。
DOI：
10.1007/s00403-015-1616-5
复制
发表时间：
2016
期刊：
影响因子：
--
通讯作者：
Meyer-Hoffert U
中科院分区：
文献类型：
--
作者：
Redelfs L;Fischer J;Weber C;Wu Z;Meyer-Hoffert U
据报道，Kazal型丝氨酸蛋白酶抑制剂（SPINK）9仅在掌跖皮肤中表达。SPINK9是丝氨酸蛋白酶激肽释放酶相关肽酶5（KLK 5）的特异性抑制剂，其有助于角质层的脱屑过程。在此，我们证明了SPINK9也在慢性单纯性苔藓中表达。此外，我们观察到SPINK9在51%的光化性角化病和鳞状细胞癌病变中表达。总之，我们证明SPINK9不仅在健康的掌跖皮肤中表达，而且在皮肤病如慢性单纯性苔藓、光化性角化病和鳞状细胞癌中也表达。
The serine protease inhibitor of Kazal-type (SPINK) 9 was reported to be exclusively expressed in palmoplantar skin. SPINK9 is a specific inhibitor of the serine protease kallikrein-related peptidase 5 (KLK5), which contributes to the desquamation process of the stratum corneum. Herein, we demonstrated that SPINK9 is also expressed in lichen simplex chronicus. Moreover, we observed expression of SPINK9 in 51 % of lesions of actinic keratosis and squamous cell carcinoma. In conclusion, we demonstrate that SPINK9 is not only expressed in healthy palmoplantar skin, but also in dermatologic disorders like lichen simplex chronicus, actinic keratosis and squamous cell carcinoma.